Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 60448 record(s)

Req # A-2023-000703

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-105282-196.

Organization: Health Canada

22 page(s)
November 2023

Req # A-2023-000744

Adverse Drug Reaction (ADR). Report number: E2B_06009811.

Organization: Health Canada

20 page(s)
November 2023

Req # A-2023-000752

Adverse Drug Reactions (ADRs) for MESALAZINE. Report numbers: 001043994, E2B_06407660, E2B_06407661, E2B_06408616, E2B_06425226, E2B_06407650, E2B_06425225, E2B_06407658, 001044905, E2B_06407664.

Organization: Health Canada

206 page(s)
November 2023

Req # A-2023-000754

Adverse Drug Reactions (ADRs) for LISDEXAMFETAMINE DIMESYLATE. Report numbers: E2B_06455930, E2B_06455955, E2B_06455965. ADRs for C1 ESTERASE INHIBITOR (HUMAN). Report numbers: E2B_06405702, E2B_06443436. ADRs for GAMMAGARD LIQUID. Report numbers: 001044600, 001044614, 001044061.

Organization: Health Canada

81 page(s)
November 2023

Req # A-2023-000768

Adverse Drug Reactions (ADRs). Report numbers: E2B_06425890, E2B_06428348.

Organization: Health Canada

18 page(s)
November 2023

Req # A-2023-000772

Adverse Drug Reaction (ADR). Report number: E2B_06463190.

Organization: Health Canada

19 page(s)
November 2023

Req # A-2023-000773

Adverse Drug Reaction (ADR). Report number: E2B_06463177.

Organization: Health Canada

20 page(s)
November 2023

Req # A-2023-000778

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-105680-705.

Organization: Health Canada

70 page(s)
November 2023

Req # A-2023-000793

Adverse Drug Reactions (ADRs). Report numbers: 001047734, 001048978, 001051498, E2B_06466757, E2B_06488895, E2B_06490275, E2B_06490283, E2B_06493113, E2B_06502414.

Organization: Health Canada

94 page(s)
November 2023

Req # A-2023-000802

Adverse Drug Reactions (ADRs). Report numbers: E2B_04745664, E2B_04199333, E2B_05046752, E2B_05084434, E2B_04670855, E2B_03997298, E2B_05094779, E2B_05628327, E2B_03587636, E2B_04337803.

Organization: Health Canada

376 page(s)
November 2023

What's new in open government?

Date modified: